Skip to main content
Skip to main navigation menu
Skip to site footer
Open Menu
About
About the Journal
Editorial board
The Publisher
Abstracting and indexing
Publication ethics
Privacy Statement
Contact
Policies
Open access policy
Editorial policies
Authors' self archiving and sharing policy
Commercial policies
Privacy policy
Guidelines
Guidelines for authors
Guidelines for Reviewers
Artwork guidelines
Publication fees
Archives
Current
Search
Register
Login
Submit now
Home
/
Archives
/
Vol. 2 No. 3 (2015): September-December 2015
Vol. 2 No. 3 (2015): September-December 2015
Published:
2015-12-31
Review
Innovation and Drugs Price and Reimbursement: A Comparison between Italy and the other Major EU Countries
Innovazione e regolazione del prezzo e del rimborso dei farmaci: un confronto tra Italia e gli altri principali Paesi europei
Claudio Jommi
117-124
PDF
Point of View
Real World Data use and Applications in the Integrated Management of Rheumatic Disease
Impiego di dati real world nella gestione integrata delle malattie reumatiche
Patrizia Berto, Silvano Adami, Costantino Botsios, Valentina Fantelli, Anna Maria Grion, Francesca Ometto, Leonardo Punzi, Chiara Roni, Giovanna Scroccaro
152-157
PDF
‘Therapeutic Alternatives’: Procurement Rules for Drugs with Same Indication but without Equivalence Certification Released According to the Balduzzi Law
Le “alternative terapeutiche”: tecniche di procurement dei farmaci aventi la medesima indicazione terapeutica ma sprovvisti di parere di equivalenza rilasciato secondo la Legge Balduzzi
Andrea Messori, Valeria Fadda, Sabrina Trippoli
158-160
PDF
Original Research Articles
Dapagliflozin as add-on to Metformin; Network Meta-Analysis and Budget Impact Analysis
Dapagliflozin in add-on a metformina: network metanalisi e analisi di impatto di budget
Edoardo Mannucci, Enrico Torre, Patrizia Berto
125-134
PDF
Economic Analysis of the Immunostimulant OM-85 for the Prevention of Paediatric Recurrent Upper Respiratory Tract Infections
Roberto Ravasio
135-142
PDF
Cost-Effectiveness Analysis of Long-Acting Bronchodilators for the Treatment of COPD (Moderate to Very Severe)
Analisi di costo-efficacia di broncodilatatori a lunga durata d'azione nel trattamento di pazienti con BPCO da moderata a molto severa: olodaterolo vs formoterolo
Roberto Ravasio
143-151
PDF
Correspondence
Il Beneficio dei Farmaci Oncologici: Commento All'Articolo di Ballatori e Colleghi
Andrea Messori, Sabrina Trippoli
161-162
PDF
Sign up
Browse
Categories
Health Technology Assessment
Health Policies
ReviewerCredits badget
banners150